The IJTLD is our flagship subscription journal for clinical research and epidemiological studies on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution.
IJTLD Open and IJTLD CRD are our open access journals (both fully compliant with Plan S) and with broader scope and coverage - see webpages for IJTLD Open and IJTLD CRD.
Our Editor-in-Chief works alongside an active Editorial Board to minimise the time taken for key peer review stages so the process is as quick as possible. Data for 2023 is:
8 Days
First Decision
3 Days
Immediate Reject
27 Days
Peer review
Please note, although authors for IJTLD and IJTLD Open submit their manuscripts via the same portal, this is to ensure we apply the same rigour to peer review for open access and subscription content. IJTLD Open has a much broader scope of coverage and content types compared to the more traditional IJTLD (see details here)
In preparing your article, please follow our Instructions for Authors:
If you exceed our recommended article lengths additional fees apply – see Journal Publication Charges
Before submission, please check you have complied with our requirements using the following documents:
If you experience difficulties of any kind, please e-mail the Editorial Office.